Daiichi Ranbaxy Buy Gives Japanese Pharma Other Indian Firms
This article was originally published in PharmAsia News
Daiichi Sankyo's acquisition of a majority share of India's Ranbaxy Laboratories also would give the Japanese drug maker a chance to get a controlling interest in another Indian pharma, Zenotech. Ranbaxy owns 48 percent of Zenotech, and Daiichi would have to make a separate offer for majority shares of that company. Ranbaxy interests in other Indian pharmas are included in the larger acquisition deal, including 14.9 percent interests each in Jupiter Bioscience, Kribs Biochemical and Orchid Pharma. (Click here for more
You may also be interested in...
Guardant’s CEO anticipates accelerated adoption and reimbursement of its FDA-approved liquid biopsy assay and more biopharma partnerships.
Public Company Edition: The German mRNA-focused company could raise up to $245m based on its proposed price range, but investor interest could drive the offering’s total higher. Also, Perceptive launches another SPAC, Regeneron sells $2bn in debt and Biohaven secures up to $950m.
Agency commissioner appeals to AMA audience to communicate message that FDA review decisions are based on good science.